Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients

Clinical Pharmacokinetics

Volumn 40, Issue 4, 2001, Pages 283-295

  Wallemacq, Pierre E ^a   Verbeeck, Roger K ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

AGE; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG USE; ERYTHROCYTE; GRAFT REJECTION; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; REVIEW;

EID: 0035010611     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140040-00004     Document Type: Review

References (96)

1. 1. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. I. fermentation, isolation and physico-chemical and biological characteristics. J Antibiotics 1987; 40: 1249-55
2. 2. Kino T. Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987; 40: 1256-65
3. 3. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506 on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19: 1284-6
4. 4. Todo S, Podesta L, Starzl TE, et al. Orthotopic liver transplantation in dogs receiving FK 506. Transplant Proc 1987; 19 Suppl. 6: 64-7
5. 5. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8
6. 6. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-5
7. 7. Ellis D. Clinical use of tacrolimus (FK506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9: 487-94
8. 8. Laskow DA, Neylan JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12: 489-503
9. 9. McDiarmid SV. The use of tacrolimus in paediatric liver transplantation. J Pediatr Gastroenterol Nutr 1998; 26: 90-102
10. 10. Reding R, de Ville de Goyet J, Sokal E, et al. Compassionate use of FK 506 in paediatric liver transplantation: a pilot study. Transplant Proc 1991; 23: 3002-4
11. 11. Reding R, Wallemacq PE, Lamy M, et al. Conversion from cyclosporin to FK506 for salvage of immunocompromised paediatric liver allografts. Transplantation 1994; 57: 93-100
12. 12. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of EBV related post transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438-42
13. 13. Siekierka JJ, Hung SH, Poe M, et al. Acytosolic binding protein for the immunosuppressant FK 506 has peptidylprolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755-7
14. 14. Harding MW, Galat A, Uehling DE, et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758-60
15. 15. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-7
16. 16. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991; 352: 803-7
17. 17. Tanaka H, Kuroda A, Marusawa H, et al. Structure of FK506; a novel immunosuppressant isolated from streptomyces. J Am Chem Soc 1987; 109: 5031-3
18. 18. Kobayashi M, Tamura K, Katayama N, et al. FK506 assay past and present-characteristics of FK506 ELISA Transplant Proc 1991; 23: 2725-9
19. 19. Firdaous I, Hassoun A, Otte JB, et al. Paediatric intravenous FK506 - how much are we really infusing? Transplantation 1994; 57: 1821-3
20. 20. Freeman DJ, Stawecki M, Howson B. Stability of FK506 in whole blood samples. Ther Drug Monit 1995; 17: 266-7
21. 21. Alak AM. Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. Ther Drug Monit 1997; 19: 338-51
22. 22. Tamura K, Kobayashi M, Hashimoto K, et al. A highly sensitive method to assay FK506 levels in plasma. Transplant Proc 1987; 19 Suppl. 6: 23-9
23. 23. Wallemacq PE, Firdaous I, Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem 1993; 39: 1045-9
24. 24. Jusko WJ, D'Ambrosio R. Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 1991; 23: 2732-5
25. 25. Beysens AJ, Wijnen RMH, Beuman GH, et al. FK506: monitoring in plasma or in whole blood? Transplant Proc 1991; 23: 2745-7
26. 26. D'Ambrosio R, Jusko WJ, Stabler T, et al. Improved procedures for enzyme immunoassay of tacrolimus (FK506) in whole blood. Clin Chem 1994; 40: 159-60
27. 27. MacFarlane G, Scheller D, Ersfeld D, et al. A simplified whole blood enzyme-linked immunosorbent assay (Pro-Trac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. Ther Drug Monit 1996; 18: 698-705
28. 28. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc 1991; 23: 2748-9
29. 29. Wallemacq PE, Leal T, Besse T, et al. IMX tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients, Clin Chem 1997; 43: 1989-91
30. 30. Michel M. Heemann U, Philipp T. Comparison of old and new IMx assays for monitoring of tacrolimus levels. Transpl Int 1997; 10: 409-10
31. 31. Takada K, Oh-Hashi M, Yoshikawa H, et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection, J Chromatogr 1990; 530: 212-8
32. 32. Beysens AJ, Beuman GH, van der Heijden JJ, et al. Determination of tacrolimus (FK506) in whole blood using liquid chromatography and fluorescence detection. Chromatographia 1994; 39: 490-6
33. 33. Perotti BYT, Prueksaritanont T, Benet LZ. HPLC assay for FK506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. Pharm Res 1994; 11: 844-7
34. 34. Friob MC, Hassoun A, Latinne D, et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients, Transplant Proc 1991; 23: 2750-2
35. 35. Firdaous I, Hassoun A, Otte JB, et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. Clin Chem 1995; 41: 1292-6
36. 36. Warty VS, Zuckerman S, Venkataramanan R, et al. FK506 measurement: comparison of different analytical methods. Ther Drug Monit 1993: 15: 204-8
37. 37. Christians U, Braun F, Kosian N, et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 1991; 23: 2741-4
38. 38. Christians U, Braun F, Schmidt M, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft patients. Clin Chem 1992; 38: 2025-32
39. 39. Gonschior AK, Christians U, Winkler M, et al. Simplified HPLC-MS assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit 1995; 17: 504-10
40. 40. Taylor PJ, Jones A, Balderson GA, et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry, Clin Chem 1996; 42: 279-85
41. 41. Zhang Q, Simpson J, Abołeneen HI. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit 1997; 19: 470-6
42. 42. Zeevi A, Eiras G. Kaufman C, et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc 1991; 23: 1406-8
43. 43. Murthy JN, Chen Y, Warty VS, et al. Radioreceptor assay for quantifying FK506 immunosuppressant in whole blood. Clin Chem 1992; 38: 1307-10
44. 44. Armstrong VW, Schuetz E, Zhang Q, et al. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). Clin Chem 1998; 44: 2516-23
45. 45. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-9
46. 46. Dressler D, Bekersky I, Lee J, et al. Effect of meal time on tacrolimus (T) bioavailability [abstract P I-90]. Clin Pharmacol Ther 1996; 59: 151
47. 47. Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokientics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994; 34: 859-64
48. 48. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991; 23: 2736-40
49. 49. Jusko WJ, Piekoszewski W, Klintmalm OB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-90
50. 50. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-30
51. 51. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75
52. 52. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995-1005
53. 53. Mekki Q, Lee C, Carrier S, et al. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients [abstract P III-92]. Clin Pharmacol Ther 1993; 53: 229
54. 54. Wallemacq PE, Furlan V, Möller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharm 1998; 23: 367-70
55. 55. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997; 12: 1668-71
56. 56. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK506 in paediatric patients receiving living-related donor liver transplantations Transplant Proc 1995; 27: 1108-10
57. 57. Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46: 113-7
58. 58. Fujisawa GmbH. Clinical pharmacokinetics of tacrolimus, 2nd ed. Munich: Fujisawa, 1997: 15-42
59. 59. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistence: multiple sequence variations and correction of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Soc 2000; 97: 3473-8
60. 60. Capone D, Gentile A, Vajro P, et al. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients J Chemother 1998; 10: 176-8
61. 61. Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340-1
62. 62. Machida M. Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK506. Transplant Proc 1991; 23: 2775-84
63. 63. Jain A, Venkataramanan R, Fung J, et al. Pregnancy in liver transplant patients under FK506 regimen. Transplantation 1993; 53: 1588-9
64. 64. Milsap RL, Hill MR, Szefler SJ. Special pharmacokinetic considerations in children. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics. Principles of therapeutic drug monitoring. Vancouver (WA): Applied Therapeutics Inc., 1992: 10-1-10-32
65. 65. Jain A, Fung JJ, Venkataramanan R, et al. Comparative study of cyclosporin and FK506 dosage requirement in adult and pediatric orthotopic liver transplantation. Transplant Proc 1991; 23: 2763-6
66. 66. Undre N, Möller A and the FK506 European Study group. Pharmacokinetic interpretation of FK506 levels in blood and in plasma during an European randomised study in primary liver transplant patients. Transpl Int 1994; 7: 15-21
67. 67. Sattler M, Guengerich FP, Yun C-Ho, et al. Cytochrome P450-3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Disp 1992; 20: 753-61
68. 14C-labelled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Disp 1999; 27: 633-6
69. 69. De Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505
70. 70. McDiarmid SV, Colonna JO, Shaked A, et al. Differences in oral FK506 dose requirements between adult and paediatric liver transplant patients. Transplantation 1993; 55: 1328-32
71. 71. Mehta P, Beltz S, Kedar A, et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1323-7
72. 72. Moreno M, Manzanares C, Castellano F, et al. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. Ther Drug Monit 1998; 20: 376-9
73. 73. Steeves M, Abdallah HY, Venkataramanan R, et al. In-vitro interaction of a novel immunosuppressant, FK506, and ant-acids. J Pharm Pharmacol 1991; 43: 574-7
74. 74. Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos Biol Fate Chem 1995; 23: 28-34
75. 75. Padhi ID, Long P, Basha M, et al. Interaction between tacrolimus and erythromycin. Ther Drug Monit 1997; 19: 120-2
76. 76. Wolter K, Wagner K, Pilipp T, et al. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207-8
77. 77. Mieles L, Venkataramanan R, Yokoyama I, et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991; 52: 1086-7
78. 78. Manez R, Martin M, Venkataraman R, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521-35
79. 79. Osowski CL, Dix SP, Lin LS, et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporin or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-72
80. 80. Assan R, Fredj G, Larger E, et al. FK506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabetes Metab 1994; 20: 49-52
81. 81. Billaud EM, Guillemain R, Tacco F, et al. Evidence for a pharmacokinetic interaction between traconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271-2
82. 82. Shapiro R, Venkataraman R, Warty VS, et al. FK506 interaction with danazol. Lancet 1993; 1: 1344-5
83. 83. Seifeldin RA, Marcos Alvarez A, et al. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother 1997; 31: 571-5
84. 84. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680-2
85. 85. Schulman SL, Shaw LM. Jabs K, et al. Interaction between tacrolimus and chloramphenicol in a renal transplant patient. Transplantation 1998; 65: 1397-8
86. 86. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16; 267-78
87. 87. Furlan V, Perello L, Jacquemin E, et al. Interactions between FK506 and rifampicin or erythromycin in paediatric liver recipients. Transplantation 1995; 59: 1217-8
88. 88. Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91-6
89. 89. Omar G, Shah IA, Thomson AW, et al. FK506 inhibition of cyclosporin metabolism by human liver microsomes. Transplant Proc 1991; 23: 934-5
90. 90. Filler G, Lampe D, Mai I, et al. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatrie renal allografts. Transplant Int 1998; 11 Suppl. 1: S82-5
91. 91. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tarcolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-28
92. 92. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical and analytical aspects. Clin Chem 1993; 39: 2219-28
93. 93. McMaster P, Mizra DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17: 602-5
94. 94. Jusko WJ, Thomson AW, Winkler M, et al. Consensus document: therapeutic drug monitoring of tacrolimus (FK506) Ther Drug Monit 1995; 17: 606-14
95. 95. Lizak P, Alak AM. Stability of FK506 in blood samples. Ther Drug Monit 1996; 18: 209-11
96. 96. Oellerich M, Armstrong VW, Schutz E, et al. Therapeutic drug monitoring of cyclosporin and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31: 309-16